ADO Co-vid latest news articles

At least some web articles starting to pop up and taking notice of ADO - next couple of months are going to be exciting if they can get this going.

https://www.technologynetworks.com/tn/product-news/anteotech-creates-rapid-high-sensitivity-covid-19-antigen-test-338849

AnteoTech Ltd has successfully developed proof-of-concept COVID-19 antigen and Flu A&B point-of-care lateral flow tests that can detect the presence of SARS-CoV-2 and influenza in less than 15 minutes. The tests utilize AnteoTech’s patented AnteoBind™ activated europium technology and provide significantly higher sensitivity than that offered by currently available COVID-19 tests. AnteoTech intends for the tests to be combined into a single multiplex test platform and be available in as little as six to nine months following clinical trials"

"Over the coming months, the COVID-19 antigen dual testing platform will enter the next stage of development to optimize function, further improve the lower limit of viral particle detection and conduct clinical studies for targeted populations and settings.AnteoTech is currently preparing for outsourced scaled manufacturing to ensure it can meet growing market demand."

https://microbiozindia.com/health-news/anteotechs-covid-19-antigen-and-flu-ab-test-distinguishes-sars-cov-2-flu-in-under-15-minutes/

https://www.news-medical.net/news/20200821/AnteoTechs-COVID-19-antigen-and-Flu-AB-test-detects-SARS-Cov-2-influenza-in-less-than-15-minutes.aspx
"Along with the COVID-19 multiplex assay, a comprehensive body of work and testing was undertaken at AnteoTech’s Brisbane labs to develop several other fast tests, such as a stage for the early detection of sepsis."

https://www.med-technews.com/news/test-developed-that-can-detect-covid-19-and-flu-in-15-minute/

https://www.livewiremarkets.com/wires/front-runners-for-a-covid-vaccine

Anteotech Ltd (ASX: ADO)

ADO’s share price increased 63.6% after the company announced it has produced multiplexed proof of concept assays using an Axxin AX-2X-S Lateral Flow Reader which are designed to provide high sensitivity concurrent detection of Covid-19 and Flu A&B in a rapid test format.

ADO has developed a proof of concept for two separate rapid tests, one for antigens using swab samples from the nose, throat and mouth, and a second for antibodies using collected blood samples. These tests are designed to deliver results in approximately 15 minutes. The company believes that the market for antibody tests is crowded and therefore will be focusing on the development of the antigen test.

ADO owns the IP for the assays developed and Axxin own the IP for the reader that is used to produce the results. ADO’s assays can be used in other reader platforms after some development work has been carried out.

The next steps for the development aim to optimise the tests, improve further the lower limit of detection, verify and validate the design, conduct clinical studies required for targeted markets, gain regulatory approvals and prepare for outsourced scaled manufacturing. The company seeks to undertake this development over the next six to nine months.

The company’s share price was up 125% for the month.

Cheers

M.oz